ClinicalTrials.gg

Program

Linagliptin

Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.

Furthest: phase 4, since Sep 21, 201189 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim800 open or runningphase 4since Sep 21, 2011Mar 31, 2006none ahead
Dong Wha Pharmaceutical30 open or runningphase 1since Aug 6, 2014Aug 6, 2014none ahead
Profil Institut für Stoffwechselforschung20 open or runningphase 4since Jul 11, 2013Jul 11, 2013none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Aug 3, 2016Aug 3, 2016none ahead
ikfe-CRO10 open or runningphase 3since Feb 11, 2015Feb 11, 2015none ahead
Marcus Borchert10 open or runningphase 4since Feb 21, 2012Feb 21, 2012none ahead
Nabiqasim Industries (Pvt)11 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: Halozyme Therapeutics, biolinerx-ltd, Eli Lilly, eva-pharma, ikfe-gmbh and mlm-medical-labs-gmbh.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Sep 21, 2011.

  1. Aug 19, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02221414, NCT02221401, NCT02220647
  2. Sep 15, 2014Phase 4 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02240680 · 302 enrolled · United States, Australia, Belgium and more
  3. Dec 11, 2014Phase 4 study in Diabetes Mellitus, Type 2Profil Institut für Stoffwechselforschung · NCT02401880 · 89 enrolled · Germany
  4. Feb 11, 2015ikfe-CRO's first study: phase 3 study in HypertensionNew to ikfe-CROikfe-CRO · NCT02376075 · 43 enrolled · Germany
  5. May 21, 2015Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02453555 · 275 enrolled · Japan
  6. Apr 29, 2016Phase 1 study in HealthyBoehringer Ingelheim · NCT02758171 · 56 enrolled · Germany
  7. Jun 24, 20162 phase 1 studies in HealthyBoehringer Ingelheim · NCT02815644, NCT02821910
  8. Aug 3, 2016Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02857946 · 24 enrolled · Egypt
  9. Aug 30, 2016Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02897349 · 206 enrolled · China
  10. Aug 22, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03259490 · 30 enrolled · Germany
  11. Feb 6, 2018Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT03429543 · 175 enrolled · United States, Argentina, Brazil and more
  12. Aug 9, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03629054 · 30 enrolled · Germany
  13. Apr 6, 20232 phase 1 studies in Healthy SubjectsDong Wha Pharmaceutical · NCT05874180, NCT05874167
  14. Feb 19, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan

TargetBeta

DPP4 →read by rule
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

The newest 60 of 89 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06862739Diabetes Mellitus · Pakistan4RecruitingNabiqasim Industries (Pvt)Apr 30, 2026800
NCT05874180Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalFeb 1, 202331
NCT05874167Healthy Subjects · Korea, Republic of1CompletedDong Wha PharmaceuticalOct 11, 202250
NCT03629054Healthy · Germany1CompletedBoehringer IngelheimNov 5, 201830
NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedBoehringer IngelheimOct 19, 2022175
NCT03259490Healthy · Germany1CompletedBoehringer IngelheimNov 13, 201730
NCT02897349Diabetes Mellitus, Type 2 · China3CompletedBoehringer IngelheimJan 11, 2019206
NCT02857946Healthy · Egypt1CompletedGenuine Research Center, EgyptMar 201624
NCT02821910Healthy · Germany1CompletedBoehringer IngelheimOct 1, 201650
NCT02815644Healthy · Japan1CompletedBoehringer IngelheimOct 5, 201622
NCT02758171Healthy · Germany1CompletedBoehringer IngelheimJul 29, 201656
NCT02453555Diabetes Mellitus, Type 2 · Japan3CompletedBoehringer IngelheimAug 26, 2016275
NCT02376075Hypertension · Germany3Completedikfe-CROSep 201443
NCT02401880Diabetes Mellitus, Type 2 · Germany4CompletedProfil Institut für StoffwechselforschungDec 201589
NCT02240680Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more4CompletedBoehringer IngelheimApr 18, 2017302
NCT02221414Healthy1CompletedBoehringer IngelheimMar 201095
NCT02221401Healthy1CompletedBoehringer IngelheimApr 201096
NCT02220647Healthy1CompletedBoehringer IngelheimApr 201096
NCT02212782Healthy · Korea, Republic of1CompletedDong Wha PharmaceuticalNov 201412
NCT02191228Renal Insufficiency1CompletedBoehringer IngelheimFeb 201051
NCT02183636Healthy1CompletedBoehringer IngelheimDec 200939
NCT02183623Healthy1CompletedBoehringer IngelheimOct 200520
NCT02183610Healthy1CompletedBoehringer IngelheimSep 200612
NCT02183584Healthy1CompletedBoehringer IngelheimOct 200916
NCT02183532Healthy1CompletedBoehringer IngelheimJul 200912
NCT02183506Healthy1CompletedBoehringer IngelheimDec 200516
NCT02183493Healthy1CompletedBoehringer IngelheimDec 200832
NCT02183480Healthy1CompletedBoehringer IngelheimSep 200912
NCT02183467Healthy1CompletedBoehringer IngelheimJun 200844
NCT02183428Healthy1CompletedBoehringer IngelheimJul 200820
NCT02183415Diabetes Mellitus, Type 21CompletedBoehringer IngelheimJan 200677
NCT02183402Healthy1CompletedBoehringer IngelheimSep 200820
NCT02183389Healthy1CompletedBoehringer IngelheimOct 200818
NCT02183376Hepatic Insufficiency1CompletedBoehringer IngelheimMar 200933
NCT02183363Healthy1CompletedBoehringer IngelheimMay 200724
NCT02183350Diabetes Mellitus, Type 21CompletedBoehringer IngelheimAug 200547
NCT02183337Healthy1CompletedBoehringer IngelheimApr 200720
NCT02183324Diabetes Mellitus, Type 22CompletedBoehringer IngelheimJun 200772
NCT02183311Healthy1CompletedBoehringer IngelheimOct 200656
NCT02183298Healthy1CompletedBoehringer IngelheimJul 200636
NCT02180503Healthy1CompletedBoehringer IngelheimOct 200524
NCT02175394Healthy1CompletedBoehringer IngelheimOct 200818
NCT02173665Healthy1CompletedBoehringer IngelheimDec 200464
NCT02173652Healthy1CompletedBoehringer IngelheimApr 200816
NCT02173639Healthy1CompletedBoehringer IngelheimJun 200920
NCT02121509Healthy · Germany1CompletedBoehringer IngelheimJul 201474
NCT02084082Healthy · Germany1CompletedBoehringer IngelheimJul 201468
NCT02084056Healthy · Germany1CompletedBoehringer IngelheimJul 201474
NCT01947153Healthy · Russian Federation1CompletedBoehringer IngelheimJan 201436
NCT01903070Diabetes Mellitus · Germany4CompletedProfil Institut für StoffwechselforschungApr 201699
NCT01897532Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more4CompletedBoehringer IngelheimJan 18, 20186,991
NCT01845077Healthy · United States1CompletedBoehringer IngelheimAug 201372
NCT01792518Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more3CompletedBoehringer IngelheimNov 2015360
NCT01708902Diabetes Mellitus, Type 2 · China, Malaysia, Philippines and more3CompletedBoehringer IngelheimApr 2014876
NCT01703286Diabetes Mellitus, Type 2 · Germany1CompletedBoehringer IngelheimJan 201442
NCT01581931Healthy · Germany1CompletedBoehringer IngelheimJun 201232
NCT01540487Healthy · China1CompletedBoehringer IngelheimJun 201248
NCT01547104Diabetes Mellitus, Type 2 · Germany4UNKNOWNMarcus BorchertOct 201240
NCT01512979Diabetes Mellitus, Type 2 · United States, Canada, India and more4CompletedBoehringer IngelheimApr 2013316
NCT01438814Diabetes Mellitus, Type 2 · Bangladesh, Belgium, Canada and more4CompletedBoehringer IngelheimMar 2013689

How it is read

Names in the registry

  • “Linagliptin”, 35 entries
  • “BI 1356”, 14 entries
  • “linagliptin”, 10 entries
  • “Linagliptin/Metformin FDC”, 4 entries
  • “BI 1356 BS”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.